Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Surgical Wound Infection 4Neoplasms 4Colorectal Neoplasms 3Rectal Neoplasms 2Pancreatic Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Sepsis 1Pancreatic Fistula 1Neutropenia 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Intestinal Neoplasms 1Inflammation 1Infections 1Hematologic Neoplasms 1Glioblastoma 1Fever 1Febrile Neutropenia 1Exanthema 1Emergencies 1Duodenal Neoplasms 1Discitis 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21venetoclax 20Standard of Care 20Sirolimus 20Azacitidine 20Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × Anti-Bacterial Agents × Clear all
NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
19 enrolled 18 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡